News
LYRA
3.600
-3.23%
-0.120
Weekly Report: what happened at LYRA last week (1208-1212)?
Weekly Report · 4d ago
Weekly Report: what happened at LYRA last week (1201-1205)?
Weekly Report · 12/08 10:39
Weekly Report: what happened at LYRA last week (1124-1128)?
Weekly Report · 12/01 10:34
Weekly Report: what happened at LYRA last week (1117-1121)?
Weekly Report · 11/24 10:39
Weekly Report: what happened at LYRA last week (1110-1114)?
Weekly Report · 11/17 10:40
Major Shareholder Sells Thousands of Lyra Therapeutics Shares!
TipRanks · 11/14 02:02
Perceptive Advisors LLC Disposes of Lyra Therapeutics Inc. Common Shares
Reuters · 11/13 22:08
Lyra Therapeutics GAAP EPS of -$3.38 beats by $0.98
Seeking Alpha · 11/13 05:53
Lyra Therapeutics Faces Financial Challenges Amid Clinical Setbacks
TipRanks · 11/13 04:21
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 11/12 22:15
LYRA THERAPEUTICS INC Q3 NET LOSS PER SHARE $3.38
Reuters · 11/12 21:01
*Lyra Therapeutics 3Q Loss/Shr $3.38 >LYRA
Dow Jones · 11/12 21:01
*Lyra Therapeutics 3Q Loss $5.98M >LYRA
Dow Jones · 11/12 21:01
Major Shareholder Sells Big Chunk of Lyra Therapeutics Stock!
TipRanks · 11/11 02:07
Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates
NASDAQ · 11/10 22:45
Perceptive Advisors LLC Reports Sale of Lyra Therapeutics Inc. Common Shares
Reuters · 11/10 22:09
Weekly Report: what happened at LYRA last week (1103-1107)?
Weekly Report · 11/10 10:37
Dentsply International (XRAY) Lags Q3 Earnings Estimates
NASDAQ · 11/06 14:15
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 11/04 14:15
Weekly Report: what happened at LYRA last week (1027-1031)?
Weekly Report · 11/03 10:37
More
Webull provides a variety of real-time LYRA stock news. You can receive the latest news about Lyra Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LYRA
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).